Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by 2O2Ovisionon Sep 30, 2023 4:32pm
240 Views
Post# 35663488

RE:Adlai Nortye

RE:Adlai Nortye@pelaboost. If you want a fairly detailed and updated picture of AN, have a look at the F1 form they just filed with the SEC for their IPO. Pela or AN1004 is mentioned a few times (p.137 of latest amended F1 is a good one). They clearly haven't moved on but rather are probably focusing on otther things while ONC sorts out their laundry. I can only assume there is something in the contract that prevents them from going at it alone in Asia which is unfortunate. They seem to have several things in the works with Roche as well which isn't a bad thing. Anyway I'm also retired and tend to avoid getting sucked into this chatboard vortex but I thought maybe you'd appreicate a good read to look up.  Cheers.
<< Previous
Bullboard Posts
Next >>